LigoCyte Receives 'Tibbetts Award' for Excellence in the Small Business Innovation Research Program

Award Based on LigoCyte's Nanoparticle Technology Program to Develop

New Asthma Therapy



Oct 03, 2000, 01:00 ET from LigoCyte Pharmaceuticals, Inc.

    BOZEMAN, Mont., Oct. 3 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc.,
 announced today that it has received the "Tibbetts Award" for being a "Model
 of Excellence" for the Small Business Innovation Research (SBIR) program.
 LigoCyte was awarded a $3.3 million SBIR grant last year to develop an asthma
 therapy based on the Company's proprietary nanoparticle technology.  The grant
 is one of the largest SBIR grants on record.
     The SBIR program, which is supervised by the U.S. Small Business
 Association (SBA), seeks to identify small businesses with novel approaches
 for success and rewards them with federal grants.  Roland Tibbetts was the
 creator of the SBIR program, and Tibbetts Awards are bestowed upon the small
 firms and individuals judged to exemplify the best in SBIR program.
     "We are honored to receive this distinction from the SBA in recognition of
 both our nanoparticle technology and our development team," said Michael A.
 McCue, President and Chief Executive Officer of LigoCyte.
     The SBIR grant awarded in 1999 funds LigoCyte's development of an
 asthma-nanoparticle therapy to block the heightened inflammatory response,
 which causes airways to constrict during an asthma attack.  LigoCyte is
 developing the asthma-nanoparticle in collaboration with the University of
 Michigan.
     According to the Asthma and Allergy Foundation of America, asthma is the
 most common and most costly illness in the Unites States.  Approximately
 17 million Americans suffer from chronic asthma, and 14 people die from asthma
 each day in the U.S.  In 1998, the cost of asthma was estimated at over
 $11 billion.
     LigoCyte's nanoparticle technology has the potential to combat asthma by
 preventing immune cells, which cause inflammation, from infiltrating lung
 tissue.  The nanoparticle is a synthetic polymer backbone upon which thousands
 of copies of biological molecules can be placed for their simultaneous
 transport to a specific tissue.  In the case of asthma, nanoparticles will be
 designed to carry small molecules or proteins that block the ability of immune
 cells to adhere to lining of the blood vessel wall.  By preventing
 "bioadhesion", the immune cells cannot exit the bloodstream and enter the
 tissue to perpetuate the inflammatory response.
     "We are aggressively developing the nanoparticle delivery platform for
 broad applications in the areas of anti-inflammatories and anti-infectives and
 are seeking additional partners to pursue the expansion of nanoparticle
 technology as a drug and vaccine delivery vehicle," said Mr. McCue.
     LigoCyte is a biotechnology company with a research focus on the molecular
 and cellular interactions associated with inflammatory disease and infectious
 diseases.  Its core expertise in cell trafficking is being applied to the
 development of novel drugs that provide new and better tools for
 anti-inflammatories, therapeutics, and vaccines.  LigoCyte's
 discovery/development process is based on the concept that the cellular and
 molecular adhesion/signaling events that contribute to the onset of infections
 are functionally similar to those associated with the inflammatory response.
 LigoCyte's patented discovery process, originally developed by LigoCyte
 scientists to study and characterize the cellular and molecular determinants
 of inflammation, has been found to be ideal for rapidly advancing new products
 to fight infectious diseases.  LigoCyte, founded in 1994, is headquartered in
 Bozeman, Montana.  For more information, please visit LigoCyte's web site at
 www.ligocyte.com.
 
 

SOURCE LigoCyte Pharmaceuticals, Inc.
    BOZEMAN, Mont., Oct. 3 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc.,
 announced today that it has received the "Tibbetts Award" for being a "Model
 of Excellence" for the Small Business Innovation Research (SBIR) program.
 LigoCyte was awarded a $3.3 million SBIR grant last year to develop an asthma
 therapy based on the Company's proprietary nanoparticle technology.  The grant
 is one of the largest SBIR grants on record.
     The SBIR program, which is supervised by the U.S. Small Business
 Association (SBA), seeks to identify small businesses with novel approaches
 for success and rewards them with federal grants.  Roland Tibbetts was the
 creator of the SBIR program, and Tibbetts Awards are bestowed upon the small
 firms and individuals judged to exemplify the best in SBIR program.
     "We are honored to receive this distinction from the SBA in recognition of
 both our nanoparticle technology and our development team," said Michael A.
 McCue, President and Chief Executive Officer of LigoCyte.
     The SBIR grant awarded in 1999 funds LigoCyte's development of an
 asthma-nanoparticle therapy to block the heightened inflammatory response,
 which causes airways to constrict during an asthma attack.  LigoCyte is
 developing the asthma-nanoparticle in collaboration with the University of
 Michigan.
     According to the Asthma and Allergy Foundation of America, asthma is the
 most common and most costly illness in the Unites States.  Approximately
 17 million Americans suffer from chronic asthma, and 14 people die from asthma
 each day in the U.S.  In 1998, the cost of asthma was estimated at over
 $11 billion.
     LigoCyte's nanoparticle technology has the potential to combat asthma by
 preventing immune cells, which cause inflammation, from infiltrating lung
 tissue.  The nanoparticle is a synthetic polymer backbone upon which thousands
 of copies of biological molecules can be placed for their simultaneous
 transport to a specific tissue.  In the case of asthma, nanoparticles will be
 designed to carry small molecules or proteins that block the ability of immune
 cells to adhere to lining of the blood vessel wall.  By preventing
 "bioadhesion", the immune cells cannot exit the bloodstream and enter the
 tissue to perpetuate the inflammatory response.
     "We are aggressively developing the nanoparticle delivery platform for
 broad applications in the areas of anti-inflammatories and anti-infectives and
 are seeking additional partners to pursue the expansion of nanoparticle
 technology as a drug and vaccine delivery vehicle," said Mr. McCue.
     LigoCyte is a biotechnology company with a research focus on the molecular
 and cellular interactions associated with inflammatory disease and infectious
 diseases.  Its core expertise in cell trafficking is being applied to the
 development of novel drugs that provide new and better tools for
 anti-inflammatories, therapeutics, and vaccines.  LigoCyte's
 discovery/development process is based on the concept that the cellular and
 molecular adhesion/signaling events that contribute to the onset of infections
 are functionally similar to those associated with the inflammatory response.
 LigoCyte's patented discovery process, originally developed by LigoCyte
 scientists to study and characterize the cellular and molecular determinants
 of inflammation, has been found to be ideal for rapidly advancing new products
 to fight infectious diseases.  LigoCyte, founded in 1994, is headquartered in
 Bozeman, Montana.  For more information, please visit LigoCyte's web site at
 www.ligocyte.com.
 
 SOURCE  LigoCyte Pharmaceuticals, Inc.